Tuesday - March 3, 2026
Rybrevant Faspro Receives U.S. FDA Breakthrough Therapy Designation for Patients With Advanced Head and Neck Cancer
February 19, 2026
RARITAN, New Jersey, Feb. 19 -- Johnson and Johnson Innovative Medicine issued the following news release on Feb. 18, 2026:

* * *

RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO(TM) beyond lung ca . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products